BC Extra | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Neuroimmunology and immuno-oncology company Alector Inc. (NASDAQ:ALEC) hired Shehnaaz Suliman as president and COO and made Richard Scheller and Thomas Südhof co-chairs of its strategic portfolio advice and review committee. Suliman was SVP of corporate...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

Buysiders and bankers expect a flood of IPOs and a stock picker's market in 4Q19 amid a continued run of sector underperformance that is only expected to get worse in 2020. As macro pressures continue...
BC Extra | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

Four biotechs set terms for U.S. IPOs Monday in a month that has already seen five go public, including the largest raise of the year. Collectively, the quartet could raise over $500 million. ADC Therapeutics...
BC Extra | Aug 27, 2019
Financial News

Aug. 27 Financial Quick Takes: Prothena gains on EcoR1 investment; plus Pharmaron, Exagen

EcoR1 takes stake in Prothena  Prothena Corp. plc (NASDAQ:PRTA) jumped $1.87 (27%) to $8.93 Tuesday after it disclosed in an SEC filing Monday that EcoR1 Capital has acquired a 23.6% stake in the neurological disorder...
BC Innovations | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
BioCentury | Apr 7, 2017
Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
BioCentury | Jan 6, 2017
Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in...
BioCentury | Jul 11, 2016
Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers...
BioCentury | Apr 4, 2016
Finance

Fundamental reset

Steve Edelson, Senior Editor   After three months of carnage, buysiders acknowledge their conservative prediction of biotech keeping pace with the broader markets is unlikely to occur this year. Instead, investors are looking for the...
Items per page:
1 - 10 of 37
BC Extra | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Neuroimmunology and immuno-oncology company Alector Inc. (NASDAQ:ALEC) hired Shehnaaz Suliman as president and COO and made Richard Scheller and Thomas Südhof co-chairs of its strategic portfolio advice and review committee. Suliman was SVP of corporate...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

Buysiders and bankers expect a flood of IPOs and a stock picker's market in 4Q19 amid a continued run of sector underperformance that is only expected to get worse in 2020. As macro pressures continue...
BC Extra | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

Four biotechs set terms for U.S. IPOs Monday in a month that has already seen five go public, including the largest raise of the year. Collectively, the quartet could raise over $500 million. ADC Therapeutics...
BC Extra | Aug 27, 2019
Financial News

Aug. 27 Financial Quick Takes: Prothena gains on EcoR1 investment; plus Pharmaron, Exagen

EcoR1 takes stake in Prothena  Prothena Corp. plc (NASDAQ:PRTA) jumped $1.87 (27%) to $8.93 Tuesday after it disclosed in an SEC filing Monday that EcoR1 Capital has acquired a 23.6% stake in the neurological disorder...
BC Innovations | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
BioCentury | Apr 7, 2017
Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
BioCentury | Jan 6, 2017
Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in...
BioCentury | Jul 11, 2016
Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers...
BioCentury | Apr 4, 2016
Finance

Fundamental reset

Steve Edelson, Senior Editor   After three months of carnage, buysiders acknowledge their conservative prediction of biotech keeping pace with the broader markets is unlikely to occur this year. Instead, investors are looking for the...
Items per page:
1 - 10 of 37